Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma

Table 3

Cox regression analysis of the prognostic factors of the patient survival period.

Variables	Univariate analysis			Multivariate analysis
	HR	95% CI		HR	95% CI
Age; (≤65 years versus >65 years)	0.83	0.45–1.53	0.551
Sex; (male versus female)	1.17	0.64–2.12	0.615
Previous resection; (no versus yes)	0.73	0.37–1.43	0.358
UICC at first therapy; (stage I versus stages II–IV)	1.20	0.96–1.50	0.133
Lobar spread of disease; (unilobar versus bilobar)	1.47	0.78–2.76	0.237
Extrahepatic metastasis; (no versus yes)	1.55	0.78–3.09	0.211
Tumor load; (≤10% versus >10%)	1.81	0.99–3.31	0.055
Number of lesions; (1 versus >1)	2.44	1.27–4.71	0.008	2.85	1.43–5.65	0.003
Portal vein thrombosis; (no versus yes)	1.43	0.62–3.30	0.407
Vascular infiltration; (no versus yes)	1.20	0.65–2.24	0.560
Ascites; (no versus yes)	1.49	0.66–3.35	0.314
Liver cirrhosis; (no versus yes)	1.25	0.67–2.34	0.493
Biliary obstruction; (no versus yes)	1.02	0.53–1.97	0.950
ECOG index; (0 versus 1–4)	1.23	0.66–2.30	0.511
CA19–9; (≤39.9 U/mL versus >39.9 U/mL)	1.93	1.01–3.68	0.047	2.05	0.99 – 4.22	0.052
CEA; (≤3.4 ng/mL versus >3.4 ng/mL)	2.30	1.23–4.31	0.009	1.89	0.97 – 3.72	0.025
Objective response; (CR + PR versus SD + PD)	2.43	1.28–4.60	0.006	2.84	1.41 – 5.72	0.003
Complications; (no versus yes)	1.06	0.68–1.67	0.796
Tumor size; (≤50 mm versus >50 mm)	1.35	0.74–2.46	0.328
Tumor size; (≤100 mm versus >100 mm)	1.22	0.60–2.50	0.585

HR, hazard ratio; CI, confidence interval; objective response categories, see Table 2.